Project Grant R43GM119880

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...

The University of California, Davis (UC Davis) has been awarded a $300,000 EAGER (Early-concept Grants for Exploratory Research) grant from the National Science Foundation (NSF) Division of Molecular and Cellular Biosciences. The grant supports a project to investigate the use of CRISPR gene editing technology to separate closely linked beneficial and harmful traits in plants. Specifically, the project aims to determine whether eliminating certain DNA repair pathways, such as the Ku-dependent...

The National Institutes of Health (NIH) awarded a $1,413,277 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Leland Stanford Junior University (Stanford University) to develop and apply two key technical innovations: 1) CRISPR-ALL, an arbitrarily combinatorial genetic perturbation platform in primary human cells, and 2) the combinatorial construction of new "non-evolved" human genes from existing functional human protein domains, initially focusing on...

This $117,074 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences program (CFDA 47.049) supports research at Lehigh University to develop biomaterial-guided CRISPR gene editing delivery systems. The key objectives are to: Determine how peptide-based nanoparticle formulation and properties impact CRISPR ribonucleoprotein (RNP) uptake, activity, and functionality. Investigate how material charge and porosity control the temporal action of CRISPR...

The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...

This $322,020 Project Grant award from the National Science Foundation's (NSF) Division of Integrative Organismal Systems will support collaborative research at the University of California, Davis (UC Davis) to develop improved methods for CRISPR/Cas9-based gene editing in maize. The key objectives are to generate maize lines expressing high levels of Cas9 nuclease and to engineer and optimize viral vectors to efficiently deliver guide RNAs for both somatic and heritable gene editing. This...

Acrigen Biosciences, Inc. was awarded a $1,000,000 cooperative agreement from the National Science Foundation under the Engineering program (CFDA 47.041) to develop a curative gene therapy for spinal muscular atrophy. Over the two year period from March 2022 to February 2024, Acrigen will engineer an anti-CRISPR protein to increase the precision and safety of CRISPR-Cas gene editing. They will pair this with a novel CRISPR nuclease and validate the system for editing and disease correction in...

The federal Project Grant award, titled "ENHANCEMENT OF GENOME EDITING IN HEMATOPOIETIC STEM CELLS BY NUCLEIC ACIDS NANOPARTICLES DELIVERY OF CRISPR/CAS SYSTEM", was granted by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $486,291 award, effective February 1, 2025 through January 31, 2028, supports the development of a nucleic acid nanoparticle technology to efficiently deliver the CRISPR/Cas9 system into...

This $1,000,000.00 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports research to characterize the molecular mechanisms by which the bridge helix (BH) region of the CRISPR-associated (Cas) 9 and Cas12a enzymes contributes to DNA cleavage fidelity. The overarching goal is to develop error-proof variants of these genome editing tools that minimize unintended off-target DNA modifications. The award includes a sub-grant to the University...